

Rick A Vreman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3389767/publications.pdf>

Version: 2024-02-01

25
papers

369
citations

1039406

9
h-index

887659

17
g-index

25
all docs

25
docs citations

25
times ranked

276
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Understanding innovation of health technology assessment methods: the IHTAM framework. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e16. | 0.2 | 2 |
| 2 | Addressing uncertainty in relative effectiveness assessments by HTA organizations. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e17. | 0.2 | 3 |
| 3 | Real World Data in Health Technology Assessment of Complex Health Technologies. <i>Frontiers in Pharmacology</i> , 2022, 13, 837302. | 1.6 | 15 |
| 4 | Reported Challenges in Health Technology Assessment of Complex Health Technologies. <i>Value in Health</i> , 2022, 25, 992-1001. | 0.1 | 9 |
| 5 | Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 9, 76-84. | 1.4 | 3 |
| 6 | Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Value in Health</i> , 2021, 24, 121-128. | 0.1 | 6 |
| 7 | Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e83. | 0.2 | 10 |
| 8 | Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00742. | 1.1 | 9 |
| 9 | Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021, 14, 1566-1577. | 1.5 | 10 |
| 10 | Early Cost-Effectiveness of Onasemnogene Apeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. <i>Value in Health</i> , 2021, 24, 759-769. | 0.1 | 24 |
| 11 | Comment on "Deterministic Sensitivity Analysis Under Ignorance". <i>Pharmacoeconomics</i> , 2021, 39, 1199-1199. | 1.7 | 0 |
| 12 | The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. <i>Pharmacoeconomics</i> , 2021, 39, 1-17. | 1.7 | 21 |
| 13 | Getting the Right Evidence After Drug Approval. <i>Frontiers in Pharmacology</i> , 2020, 11, 569535. | 1.6 | 10 |
| 14 | Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8309. | 1.2 | 20 |
| 15 | Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. <i>Drug Discovery Today</i> , 2020, 25, 1223-1231. | 3.2 | 11 |
| 16 | Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357. | 2.3 | 41 |
| 17 | A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. <i>European Journal of Health Economics</i> , 2020, 21, 845-853. | 1.4 | 1 |
| 18 | Efficacy gap between phase II and subsequent phase III studies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1306-1313. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. <i>Value in Health</i> , 2020, 23, 10-16. | 0.1 | 37 |
| 20 | Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 54. | 0.6 | 2 |
| 21 | The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020, , . | 0.5 | 8 |
| 22 | Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 883-893. | 1.0 | 15 |
| 23 | Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. <i>Value in Health</i> , 2019, 22, 1275-1282. | 0.1 | 65 |
| 24 | Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 684-691. | 2.3 | 34 |
| 25 | Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. <i>Pharmacogenomics</i> , 2017, 18, 1143-1153. | 0.6 | 5 |